April 26th 2024
Cellular therapies are an effective option in hematologic malignancies but have been slower to develop in AML, but identifying new targets paves the way for evolving treatments.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Prognostic Biomarkers for Venetoclax and Hypomethylating Agents Therapy for AML
April 9th 2021Danielle Hammond, MD, discusses prognostic factors indicating therapy success for patients with acute myeloid leukemia treated with a combination of venetoclax (Venclexta) and either decitabine or azacitadine.
Watch
Enrollment Milestone Reached for Phase 3 Study of Devimistat in AML
April 2nd 2021The phase 3 ARMADA 2000 trial, which aims to determine the efficacy and safety of devimistat in combination with high-dose cytarabine and mitoxantrone compared to controls for older patients with relapsed or refractory acute myeloid leukemia, has crossed the enrollment of 150 participants.
Read More
FDA Approves a Revised Indication for Daunorubicin/Cytarabine for the Treatment of Pediatric AML
March 31st 2021The FDA has revised the approval of daunorubicin and cytarabine to add 2 new indications for the treatment of newly diagnosed therapy-related acute myeloid leukemia or for AML with myelodysplasia-related changes in pediatric patients aged 1 year and older.
Read More
Gilteritinib Prolongs OS Over Chemotherapy in FLT3 + Acute Myeloid Leukemia
March 30th 2021Gilteritinib showed improvement in overall survival in patients with relapsed or refractory FLT3 mutation-positive acute myeloid leukemia compared with chemotherapy, meeting the primary end point of the phase 3 COMMODORE confirmatory trial.
Read More
Aiming for OS Improvement in AML With Venetoclax Plus FLAG-IDA Induction/Consolidation
March 8th 2021Curtis Lachowiez, MD, discusses the interim analysis of the phase 1b/2 study of venetoclax in combination with standard intensive acute myeloid leukemia induction plus consolidation therapy with the FLAG-IDA regimen as treatment of patients with newly diagnosed or relapsed/refractory AML
Watch
Novel T-Cell Based Immunotherapy Dosed Phase 2 Study of Patients With AML
March 3rd 2021The first patient with acute myeloid leukemia in a phase 2 trial of the MultiTAA-specific T cell, MT-401 followed stem-cell transplant has been dosed with the agent, according to a press release by Marker Therapeutics, Inc.
Read More
Iomab-B Conditioning Therapy Leads to Successful HCT in Active AML
February 11th 2021Targeted radioimmunotherapy to the marrow with apamistamab conditioning therapy led to high rates of allogeneic hematopoietic stem cell transplant in patients with active, relapsed, or refractory acute myeloid leukemia, according to interim data from the phase 3 SIERRA trial.
Read More
JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS
February 9th 2021A phase 1 study is the first to demonstrate that JSP191 is safe and effective in older patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.
Read More
Combination of Venetoclax and Hypomethylating Agents Show Efficacy in AML
February 1st 2021Danielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.
Watch
Younger Patients, Select Subsets in AML May Have Higher Chances of Long-Term Survival
January 9th 2021Ten-year overall survival is low among patients with acute myeloid leukemia , but an analysis demonstrated that survival is shorter for older patients treated with chemotherapy alone, according to published findings.
Read More
Phase 3 Study of Iomab-B With Bone Marrow Transplant in AML to Continue to Full Enrollment
January 5th 2021An Independent Data Monitoring Committee has recommended the pivotal phase 3 SIERRA study continue as planned to full enrollment of 150 patients based on the findings from a pre-planned ad hoc interim analysis of the study.
Read More
Sabatolimab Demonstrates Promising Efficacy in Acute Myeloid Leukemia, Myelodysplastic Syndrome
January 2nd 2021In a phase 1b clinical trial presented during the 2020 American Society of Hematology Annual Meeting, investigators sought to determine the efficacy and safety of the novel TIM-3–targeting IgG4 antibody sabatolimab in combination with hypomethylating agents as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.
Read More
Sabatolimab Appears Promising for Combination Use With HMAs in AML, MDS
December 25th 2020Andrew M. Brunner, MD, shares his key take home message from a phase 1b clinical trial investigating sabatolimab as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.
Watch
LACEWING Update: Gilteritinib Plus Azacitidine Does Not Improve OS in Newly Diagnosed AML
December 21st 2020A review by an Independent Data Monitoring Committee determined that combination of gilteritinib plus azacitidine would not likely improve overall survival compared with azacitidine alone in patients newly diagnosed FLT3-positive acute myeloid leukemia who were ineligible for intensive induction chemotherapy, missing the primary end point of the phase 3 LACEWING clinical trial.
Read More
Higher CPX-351 Induction Doses Lead to Delayed Hematologic Recovery in AML
December 8th 2020Treatment with higher doses of CPX-351 in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia was significantly associated with prolonged hematologic recovery times during induction cycles 1 and 2.
Read More
High-/Low-Dose Sabatolimab Exhibit Comparable Pharmacokinetics in MDS and AML
December 6th 2020In patients with acute myeloid leukemia and myelodysplastic syndrome, treatment with sabatolimab administered at 200 mg every 2 weeks and 800 mg every 4 weeks demonstrated similar pharmacokinetic activity, according to findings from a dose-selection and dose-response analysis presented during the 2020 American Society of Hematology Annual Meeting.
Read More